greeksoup/ stock research
Stock research / United States / LLY · Pharmaceutical Preparations · NYSE

Eli Lilly & Co. (LLY)

Eli Lilly discovers, develops, manufactures and markets human pharmaceutical products, and reports as a single business segment. It was incorporated in Indiana in 1901, succeeding the drug manufacturing business founded in Indianapolis in 1876 by Colonel Eli Lilly. It manufactures and distributes through facilities in the United States, including Puerto Rico, and in Europe and Asia, and its products are sold in approximately 90 countries.

Eli Lilly & Co.

Eli Lilly discovers, develops, manufactures and markets human pharmaceutical products, and reports as a single business segment. It was incorporated in Indiana in 1901, succeeding the drug manufacturing business founded in Indianapolis in 1876 by Colonel Eli Lilly. It manufactures and distributes through facilities in the United States, including Puerto Rico, and in Europe and Asia, and its products are sold in approximately 90 countries.

What it sells

Four therapeutic areas. Cardiometabolic health holds the insulins: Humalog and the insulin lispro family, Humulin, and Basaglar, a long-acting human insulin analog sold with Boehringer Ingelheim. Alongside them sit Jardiance, also with Boehringer Ingelheim, for type 2 diabetes and for reducing the risk of cardiovascular death, heart failure hospitalisation and decline in kidney function; Trulicity for type 2 diabetes in adults and children aged 10 and over; Mounjaro, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist for type 2 diabetes; and Zepbound, for adults with obesity or overweight with at least one weight-related condition and for moderate to severe obstructive sleep apnea in adults with obesity, sold under the Mounjaro name for those indications in various markets outside the United States.

Oncology covers Verzenio, used alone or with endocrine therapy for HR+, HER2- breast cancer; Jaypirca for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma; Retevmo for cancers carrying a RET gene fusion or mutation; Cyramza and Erbitux, used alone or with other agents across gastric, lung, colorectal, liver and head and neck cancers; Inluriyo for ESR1-mutated advanced breast cancer; and Tyvyt, sold in China with Innovent Biologics.

Immunology covers Taltz for plaque psoriasis, psoriatic arthritis and spondyloarthritis; Omvoh for ulcerative colitis and Crohn's disease; Ebglyss for atopic dermatitis, sold in Europe with Almirall; and Olumiant, with Incyte, for rheumatoid arthritis, atopic dermatitis, severe alopecia areata and hospitalised COVID-19 patients needing respiratory support. Neuroscience covers Emgality for migraine prevention and episodic cluster headache, and Kisunla for adults with early symptomatic Alzheimer's disease with confirmed amyloid pathology.

How it reaches the patient

Healthcare providers are reached through online and other promotion, information and samples, medical meetings, and sales representatives who are employees or contractors. In the United States the company also advertises certain products directly to consumers. Its account managers deal with wholesalers, pharmacy benefit managers, insurers, plan sponsors, employers, managed care organisations, group purchasing organisations, government and long-term care institutions, hospitals and certain retail pharmacies, and those arrangements often carry discounts or rebates.

Most United States products are distributed through wholesalers serving pharmacies, physicians and hospitals, and in 2025, 2024 and 2023 the filing names three of them, McKesson, Cencora and Cardinal Health, as each accounting for a large part of consolidated revenue. No other customer accounted for more than 10 percent in any of those years. In certain jurisdictions the company also runs LillyDirect, a direct-to-patient digital health care platform through which selected Lilly medicines are dispensed by third-party pharmacies and delivered to patients, and which also carries tools for reaching independent healthcare providers and programmes for treatment adherence. Outside the United States it promotes through its own sales organisations in many countries and through third parties engaged under distribution and promotion arrangements.

Research, and where the medicines are made

At the end of 2025 approximately 12,000 people worked in pharmaceutical research and development, including physicians, scientists with graduate or postgraduate degrees and technical staff. Internal research focuses on the same four areas the products sit in, and the company supplements it by collaborating with academic institutions and other pharmaceutical and biotechnology companies.

Active ingredient manufacturing and finishing, which covers formulation, filling, assembly, delivery device manufacturing and packaging, is done at sites in the United States including Puerto Rico, in Ireland and at a number of other sites worldwide. To meet expected demand the company has undertaken manufacturing expansion, with new sites in North Carolina, Wisconsin, Indiana, Virginia, Texas, Alabama, Pennsylvania, Ireland, Germany and the Netherlands. Third parties handle some active ingredient manufacturing, filling and finishing and some device and component production. Most principal materials are available from more than one source, though certain materials come from a single source, and the filing notes that the company and the industry generally depend on China-based suppliers for portions of the supply chain.

From Eli Lilly's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Eli Lilly became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 29 October 2026
Revenue
$24.4 billion
+38.6% on the year · +6.2% on the quarter
Q4 FY2024Q3 FY2026
Net income
$6.5 billion
+15.6% on the year · -9.1% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$7.22
+16.3% on the year · -9.1% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 12 February 2026
Revenue
$65.2 billion
+44.7% on the year
FY2018FY2025
Net income
$20.6 billion
+94.9% on the year
FY2018FY2025
Diluted EPS
$22.95
+96.0% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsEli Lilly (LLY) reported revenue of $65.2 billion for fiscal 2025, the year ended 31 December 2025, up 44.7% on the year before. Net income was $20.6 billion and diluted earnings per share $22.95. Revenue was $45.0 billion in fiscal 2024, $34.1 billion in fiscal 2023, $28.5 billion in fiscal 2022 and $28.3 billion in fiscal 2021. Net income in the same years was $10.6 billion, $5.2 billion, $6.2 billion and $5.6 billion. Over the twelve months to 30 September 2026, Eli Lilly reported revenue of $86.5 billion and net income of $27.6 billion. Revenue grew 21.6% a year, compounded, over the five years to fiscal 2025. Eli Lilly declared $6.23 a share in dividends over the last four quarters and had 941 million shares outstanding at the latest filed count. At 30 September 2026 it carried $49.5 billion of debt and $4.9 billion of cash. At the close of 6 November 2026 the market cap of Eli Lilly was $1.27 trillion, 44.0 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE68.5%
ROCEn/a
Operating marginn/a
Net margin31.9%
FCF margin22.7%
Interest covern/a
Debt to equity1.23x
Cash conversion1.11x
Share count, last 12 months-0.5%
Sales CAGR, 3 years31.7%
Profit CAGR, 3 years49.0%
EPS, TTM$30.81

At the close of 6 November 2026

Price$1,354.96
Market cap$1.27 trillion
Stock P/E44.0x
Price to book31.6x
EV / EBITDAn/a
Dividend yield0.5%
Market cap / sales14.7x
52-week high$1,418.07
52-week low$851.21
Price, 1 year44.5%
Price CAGR, 3 years31.2%
Price CAGR, 5 years38.6%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Eli Lilly & Co.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.
LLYgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022 †Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue8,0007,8106,4886,9427,3026,9608,3129,4999,3538,76811,30311,43913,53312,72815,55817,60119,29219,79922,97424,397
Cost of revenue2,0502,0721,4301,5791,5481,6271,8071,8601,7881,6742,1702,1712,4042,2242,4483,0083,3723,5773,2683,933
Gross profit5,9505,7385,0585,3625,7545,3336,5057,6387,5657,0949,1339,26811,12910,50413,11014,59215,92016,22219,70620,464
Gross margin74%73%78%77%79%77%78%80%81%81%81%81%82%83%84%83%83%82%86%84%
R&D1,9591,6101,7821,8031,9961,9852,3562,4092,5632,5232,7112,7343,0222,7343,3363,4663,8023,5103,8194,247
SG&A1,5921,5581,6251,6141,6431,7491,9251,8041,9251,9522,1172,1002,4242,4692,7532,7413,1322,9343,4303,125
Interest expense81.584.981.281.584.0103120125138180184193225244249180223n/an/an/a
Pre-tax income1,8402,0541,0911,5662,0961,5302,0894272,5092,5363,5171,5885,0393,4566,7767,2328,2668,8509,2478,406
Tax rate6%7%13%7%8%12%16%113%13%12%16%39%12%20%16%23%20%16%23%23%
Net income1,7261,9039521,4521,9381,3451,763-57.42,1902,2432,9679704,4102,7595,6605,5826,6387,3967,0956,451
Net margin22%24%15%21%27%19%21%-1%23%26%26%8%33%22%36%32%34%37%31%26%
Diluted EPS$1.88$2.10$1.05$1.61$2.14$1.49$1.95-$0.06$2.42$2.48$3.28$1.07$4.88$3.06$6.29$6.21$7.39$8.26$7.94$7.22
Operating cash flow2,1562,5238212,1851,5801,7316322,190-3121,1661,4663,7122,4741,6663,0878,8363,2255,33310,69011,397
Capital expenditure2913653716175016687389701,0719861,2251,3511,4961,5101,6972,0882,5472,3262,9333,178
Free cash flow1,8652,1584501,5681,0791,062-1061,219-1,3821802412,3619781561,3906,7486783,0077,7578,219
Buybacks7501,5000.00.00.07500.00.00.00.00.04462,0541,2006927081,5082,3561,601377
Dividends paid7738868848828841,0171,0181,0161,0181,1691,1721,1701,1681,3461,3471,3451,3461,5481,5461,541
Shares outstanding952m950m950m950m950m949m949m949m950m950m950m949m948m948m946m945m943m942m941m941m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008 †FY2009 †FY2010 †FY2011FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019FY2020 †FY2021 †FY2022 †FY2023FY2024 †FY2025TTM
Revenue18,63420,37221,83623,07624,28622,60323,11319,61619,95918,31319,97421,49322,32024,54028,31828,54134,12445,04365,17986,462
Cost of revenue4,2494,3774,2474,3665,0684,7964,9084,9325,0374,1604,4484,6824,7215,4837,3136,6307,0828,41811,05214,150
Gross profit14,38515,99517,58918,71019,21917,80718,20514,68314,92214,15215,52616,81217,59819,05621,00621,91227,04236,62454,12772,312
Gross margin77.2%78.5%80.6%81.1%79.1%78.8%78.8%74.9%74.8%77.3%77.7%78.2%78.8%77.7%74.2%76.8%79.2%81.3%83.0%83.6%
Research and development3,4873,8414,3264,8845,0215,2785,5314,7344,7965,0405,0965,0515,5955,9766,9317,1919,31310,99113,33715,378
Selling, general and administrative6,0956,6266,8927,0537,8807,5147,1266,6216,5335,8425,9825,9756,2146,1216,4326,4407,4038,59411,09412,620
Interest expensen/a-228261186186178160149161185225242401360340332486781895n/a
Pre-tax income3,877-1,3085,3586,7676,1394,9025,8893,0002,7903,2762,3053,6805,2667,2306,1566,8066,55512,68025,73134,769
Income tax9247641,0291,4561,0021,3201,2046103825512,3915306281,0365745621,3142,0905,0917,189
Effective tax rate23.8%n/a19.2%21.5%16.3%26.9%20.5%20.3%13.7%16.8%103.7%14.4%11.9%14.3%9.3%8.3%20.1%16.5%19.8%20.7%
Net income2,953-2,0724,3295,0704,3484,0894,6852,3902,4082,738-2043,2328,3186,1945,5826,2455,24010,59020,64027,580
Net margin15.8%-10.2%19.8%22.0%17.9%18.1%20.3%12.2%12.1%14.9%-1.0%15.0%37.3%25.2%19.7%21.9%15.4%23.5%31.7%31.9%
Diluted EPSn/a-$1.89$3.94$4.58$3.90$3.66$4.32$2.23$2.26$2.58-$0.19$3.13$8.89$6.79$6.12$6.90$5.80$11.71$22.95$30.81
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K8-K8-K8-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by product or service FY2017 to FY2025

FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Net product revenue18,77619,86620,37722,69525,95825,46328,81440,74860,95893.5%
Collaboration and Other Revenue1,1971,6271,9421,8452,360n/a5,3104,2954,2216.5%
Basaglar®n/an/an/an/an/a760n/an/an/an/a
COVID-19 Antibodiesn/an/an/an/an/a2,020n/an/an/an/a
Tyvytn/an/an/an/an/a293n/an/an/an/a
Net product revenueCollaboration and Other Revenue FY2017 to FY2025COVID-19 Antibodies FY2022Basaglar® FY2022Tyvyt FY2022
20.0FY201722.3FY201928.3FY202134.1FY202365.2FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Revenue by region FY2010 to FY2025, 1 year left out

FY2010FY2011FY2012FY2013FY2014FY2015FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States12,86612,97712,31312,8909,13410,09711,41412,39212,72314,22916,81118,19021,79130,37543,48166.7%
Europe5,1065,2914,2604,3384,5073,9443,3913,6633,7654,1884,7774,2996,1756,92111,55817.7%
Rest of worldn/an/an/an/an/an/an/an/an/an/an/a2,8522,9464,2716,0579.3%
Japan1,6172,1042,2462,0642,0272,0332,3402,4072,5482,5832,3671,7471,6731,8152,1323.3%
Chinan/an/an/an/an/an/an/a7519391,1171,6611,4531,5401,6601,9513.0%
Other foreign countries3,4873,9143,7843,8213,9483,8852,8292,2802,3452,4232,702n/an/an/an/an/a
United StatesEuropeRest of world FY2022 to FY2025JapanChina FY2018 to FY2025Other foreign countries FY2010 to FY2021
23.1FY201022.6FY201219.6FY201420.0FY201722.3FY201928.3FY202134.1FY202365.2FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2007FY2008 †FY2009 †FY2010 †FY2011FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019FY2020 †FY2021 †FY2022 †FY2023FY2024 †FY2025TTM
Operating cash flow5,1547,2964,3366,8577,2345,3055,7354,4582,9654,8515,6165,5244,8376,5007,3667,5864,2408,81816,81330,645
Capital expenditure1,0829477656946729051,0121,1631,0661,0371,0771,2111,0341,3881,3101,8543,4485,0587,84110,984
Free cash flow4,0726,3483,5706,1626,5624,3994,7233,2961,8983,8144,5394,3143,8035,1126,0565,7317923,7608,97219,661
Free cash flow margin21.9%31.2%16.4%26.7%27.0%19.5%20.4%16.8%9.5%20.8%22.7%20.1%17.0%20.8%21.4%20.1%2.3%8.3%13.8%22.7%
Cash from investing-4,328-7,269143-3,160-4,824-2,833-2,073-3,90926.8-3,139-3,7841,906-8,083-2,259-2,868-3,763-7,153-9,302-10,972-30,413
Cash from financing-8452,346-5,534-2,022-2,370-4,420-3,829-166-3,111-560143-5,905-2,324-3,137-4,131-5,4073,4961,230-2,213-5,142
Depreciation and amortisation-1,0481,1231,2981,3281,3741,4621,4461,3791,4281,4971,5671,6091,2331,3241,5481,5221,5271,7671,9972,174
Share-based compensation282255368231147142145156218255281280312308343371628646626698
Buybacksn/an/an/a0.00.07211,6988007506003004,1514,4005001,2501,5007502,5004,1085,842
Dividends paid1,8542,0572,1522,1652,1802,1872,1212,1012,1272,1582,1922,3122,4102,6873,0873,5364,0694,6805,3845,980
Dividend per sharen/a$1.90$1.96$1.96$1.96n/an/an/an/a$2.05$2.12$2.33$2.68$3.07$3.53$4.07$4.69$5.40$6.23n/a
Diluted shares, weightedn/a1,094m1,098m1,106m1,114m1,117m1,085m1,074m1,066m1,062m1,052m1,034m936m913m912m905m903m904m899m893m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a941m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K8-K8-K8-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008 †FY2009 †FY2010 †FY2011FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019FY2020 †FY2021 †FY2022 †FY2023FY2024 †FY2025TTM
Funded by
Shareholders' equityn/a6,7389,52512,42013,54214,76517,63115,37314,57114,00811,5929,8292,6075,6428,97910,65010,77214,27226,53540,271
Non-controlling interestn/an/an/a-7.5-6.18.79.314.919.072.875.71,08092.218417612691.879.5n/an/a
Short-term borrowingsn/a5,84627.4n/a1,52211.9n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Debtn/a4,6166,6556,9266,9825,5315,2138,0227,97810,30513,64710,29915,31716,59516,88516,23925,22533,64442,50349,503
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/a0.0487n/an/an/a9489711,140n/a
Other liabilitiesn/a12,01311,25311,66211,62014,08212,39512,89813,00014,42019,66622,70120,78324,21322,76622,47626,96929,74842,29858,298
Total liabilities and equityn/a29,21327,46131,00133,66034,39935,24936,30835,56938,80644,98143,90839,28646,63348,80649,49064,00678,715112,476148,072
Owned
Fixed assetsn/a8,6268,1977,9417,7607,7607,9767,9648,0548,2537,8857,9967,8738,6828,98510,14412,91417,10224,67532,188
Goodwilln/an/a1,1751,4241,4351,5011,5171,7584,0403,9731,3781,3673,6793,7663,8924,0734,9405,7705,8989,874
Intangible assetsn/an/an/an/an/a3,1862,8142,8845,0354,3581,3541,0686,6187,4507,6927,2076,9076,1666,52118,084
Investmentsn/a1,9741,1902,5135,0047,9799,1925,5244,4326,6647,1642,0942,0632,9913,3033,0473,1613,3712,8024,013
Cash and equivalents3,2205,4974,4635,9935,9224,0193,8303,8723,6664,5826,2127,3212,3383,6573,8182,0672,8193,2687,2684,885
Receivablesn/a2,7793,3433,4943,5983,3363,4343,2353,5134,0293,9774,5944,5475,8756,6736,8969,09011,00617,76022,089
Inventoryn/a2,4932,8502,5182,3002,6442,9292,7403,4463,5623,3963,0983,1913,9803,8864,3105,7737,58913,74418,194
Other assetsn/a7,8446,2427,1197,6403,9733,5578,3313,3843,38513,61416,3718,97710,23110,55711,74718,40324,44233,80838,745
Total assetsn/a29,21327,46131,00133,66034,39935,24936,30835,56938,80644,98143,90839,28646,63348,80649,49064,00678,715112,476148,072
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K8-K8-K8-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded12.6%21.6%31.7%45.5%
Profit growth, compounded24.0%27.2%49.0%49.8%
Return on equity, average80.1%64.3%66.9%77.8%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Eli Lilly's revenue in fiscal 2025?

Eli Lilly (LLY) reported revenue of $65.2 billion for fiscal 2025, the year ended 31 December 2025, up 44.7% on the year before.

How much did Eli Lilly earn in fiscal 2025?

Net income was $20.6 billion for fiscal 2025, and diluted earnings per share $22.95.

What is Eli Lilly's P/E ratio?

At the close of 6 November 2026, Eli Lilly traded at 44.0 times its earnings over the twelve months to 30 September 2026.

What is Eli Lilly's market cap?

The market cap of Eli Lilly was $1.27 trillion at the close of 6 November 2026.

Does Eli Lilly pay a dividend?

Yes. Eli Lilly declared $6.23 a share in dividends over the four quarters to 30 September 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on LLY

Dividends$6.23 a share in FY2025
Filings17 in twelve months: 7 current reports (8-K), about 4 results of operations; 1 other events; 1 shareholder vote; 1 officer or director change
Planned insider sales19 Form 144 notices in twelve months, $4.96 billion; latest 30 October 2026
Options tapeput/call 1.4 by open interest at the 6 November 2026 close; the straddle prices a 3.9% move to 13 November 2026
13F holders4,662 funds reported a position for the quarter to 30 June 2026; largest Lilly Endowment Inc.
Insider trading178 sales and 0 purchases on Form 4 in twelve months
Congress5 House trades disclosed in six months
Short interest7.0 million shares short, 3.04 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202629 October 2026EDGAR
10-Q30 June 20265 August 2026EDGAR
10-Q31 March 202630 April 2026EDGAR
10-K31 December 202512 February 2026EDGAR
10-Q30 September 202530 October 2025EDGAR
10-Q30 June 20257 August 2025EDGAR
10-Q31 March 20251 May 2025EDGAR
10-K31 December 202419 February 2025EDGAR
10-Q30 September 202430 October 2024EDGAR
10-Q30 June 20248 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.